US5932247A - Pharmaceutical composition for piperidinoalkanol compounds - Google Patents
Pharmaceutical composition for piperidinoalkanol compounds Download PDFInfo
- Publication number
- US5932247A US5932247A US08/948,005 US94800597A US5932247A US 5932247 A US5932247 A US 5932247A US 94800597 A US94800597 A US 94800597A US 5932247 A US5932247 A US 5932247A
- Authority
- US
- United States
- Prior art keywords
- hydroxydiphenylmethyl
- water
- piperidinyl
- hydroxybutyl
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
TABLE 1 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 11.8 30 7.3 30 6.3 65 5.9 35 5.0 45 4.8 100 4.4 45 3.9 60 3.8 75 3.7 30 ______________________________________
TABLE 2 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 9.0 95 4.9 100 4.8 35 4.6 25 4.5 25 3.7 25 ______________________________________
TABLE 3 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 7.8 45 6.4 44 5.2 85 4.9 60 4.7 80 4.4 55 4.2 50 4.1 60 3.7 75 3.6 60 3.5 50 ______________________________________
TABLE 4 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 10.4 60 7.0 45 6.4 50 5.3 100 5.2 55 4.3 75 4.1 50 4.0 45 3.8 60 3.5 55 ______________________________________
TABLE 5 ______________________________________ Preferred Amounts of Inert Ingredients Preferred #1 #2 #3 #4 #5 #6 #7 Combination (%) (%) (%) (%) (%) (%) (%) ______________________________________ Croscarmellose 4.8 4.8 -- -- 4.8 6 -- Sodium (4.6) Micro- 33.8 33.7 34.9 36.5 25.7 33.3 21.1 crystalline (32.4) (33.5) (35.1) Cellulose Lactose 33.8 33.7 -- -- 25.7 -- -- (32.4) Pregelatinized 9.6 9.6 29.4 31.0 9.6 30 30 Starch (9.2) (28.3) (29.8) Gelatin 3.5 3.5 3.3 -- 3.5 -- -- (3.4) (3.1) Magnesium -- 0.5 0.5 0.5 0.75 0.75 0.75 Stearate (0.5) (0.5) (0.5) Calcium -- -- 15.6 15.6 -- -- 15.6 Carbonate (15.0) (15.0) Sodium Starch -- -- 5.6 5.6 -- -- 10.0 Glycolate (5.4) (5.4) ______________________________________
TABLE 6 ______________________________________ Composition of 20 mg Gelatin Capsules AMOUNT COMPOSITION INGREDIENT mg/capsule % by weight ______________________________________ Piperidinoalkanol Compound* 20.0 14.4 Microcrystalline Cellulose 47.0 33.8 Lactose 47.0 33.8 Pregelatinized Starch 13.3 9.6 Croscarmellose Sodium 6.7 4.8 Gelatin 4.9 3.5 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 7 ______________________________________ Composition of 30 mg Capsules AMOUNT COMPOSITION INGREDIENT mg/capsule % by weight ______________________________________ Piperidinoalkanol Compound* 30.0 14.4 Microcrystalline Cellulose 70.5 33.8 Lactose 70.5 33.8 Pregelatinized Starch 20.0 9.6 Gelatin 7.3 3.5 Croscarmellose Sodium 10.0 4.8 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 8 ______________________________________ Composition of 30 mg Capsules AMOUNT COMPOSITION INGREDIENT mg/capsule % by weight ______________________________________ Piperidinoalkanol Compound* 30.0 14.3 Microcrystalline Cellulose 70.5 33.7 Lactose 70.5 33.7 Pregelatinized Starch 20.0 9.6 Gelatin 7.3 3.5 Croscarmellose Sodium 10.0 4.8 Magnesium Stearate 1.0 0.5 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 9 ______________________________________ Composition of 40 mg Gelatin Capsules AMOUNT COMPOSITION INGREDIENT mg/capsule % by weight ______________________________________ Piperidinoalkanol Compound* 40.0 14.4 Microcrystalline Cellulose 94.0 33.8 Lactose 94.0 33.8 Pregelatinized Starch 26.6 9.6 Croscarmellose Sodium 13.3 4.8 Gelatin 9.8 3.5 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 10 ______________________________________ Composition of 60 mg Capsules AMOUNT COMPOSITION INGREDIENT mg/capsule % by weight ______________________________________ Piperidinoalkanol Compound* 60.0 14.4 Microcrystalline Cellulose 141.0 33.8 Lactose 141.0 33.8 Pregelatinized Starch 40.0 9.6 Croscarmellose Sodium 20.0 4.8 Gelatin 14.7 3.5 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 11 ______________________________________ Composition of 30 mg Tablets AMOUNT COMPOSITION INGREDIENT mg/tablet % by weight ______________________________________ Piperidinoalkanol Compound* 30.0 14.3 (13.8) Microcrystalline Cellulose 70.5 33.7 (32.4) Lactose 70.5 33.7 (32.4) Pregelatinized Starch 20.0 9.6 (9.2) Croscarmellose Sodium 10.0 4.8 (4.6) Gelatin 7.3 3.5 (3.4) Magnesium Stearate 1.0 0.5 (0.5) Opadry YS-1-18027-A 6.3 -- (2.9) Opadry YS-1-19016 2.2 -- (1.0) ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 12 ______________________________________ Composition of 30 mg Tablets AMOUNT COMPOSITION INGREDIENT mg/tablet % by weight ______________________________________ Piperidinoalkanol Compound* 30.0 10.7 (10.3) Microcrystalline Cellulose 97.7 34.9 (33.5) Calcium Carbonate 43.7 15.6 (15.0) Pregelatinized Starch 82.3 29.4 (28.3) Gelatin 9.1 3.3 (3.1) Sodium Starch Glycolate 15.7 5.6 (5.4) Magnesium Stearate 1.5 0.5 (0.5) Opadry YS-1-18027-A 8.4 -- (2.9) Opadry YS-1-19016 2.9 -- (1.0) ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 13 ______________________________________ Composition of 30 mg Tablets AMOUNT COMPOSITION INGREDIENT mg/tablet % by weight ______________________________________ Piperidinoalkanol Compound* 30.0 10.7 (10.3) Microcrystalline Cellulose 102.2 36.5 (35.1) Calcium Carbonate 43.7 15.6 (15.0) Pregelatinized Starch 86.9 31.0 (29.8) Sodium Starch Glycolate 15.7 5.6 (5.4) Magnesium Stearate 1.5 0.5 (0.5) Opadry YS-1-18027-A 8.4 -- (2.9) Opadry YS-1-19016 2.9 -- (1.0) ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 14 ______________________________________ Composition of 180 mg Tablets Amount Composition INGREDIENT mg/tablet % Weight ______________________________________ Piperidinoalkanol Compound* 180.0 30.0 Microcrystalline Cellulose 199.5 33.3 Pregelatinized Starch 180.0 30.0 Croscarmellose Sodium 36.0 6.0 Magnesium Stearate 4.5 0.75 ______________________________________ *4- 4(4-(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimeth lbenzeneacetic acid hydrochloride with a particle surface area of about 2- m.sup.2 /g.
TABLE 15 ______________________________________ Composition of 180 mg Tablets Amount Composition INGREDIENT mg/tablet % weight ______________________________________ Piperidinoalkanol Compound* 180.0 mg 22.5 Microcrystalline Cellulose 169.0 21.1 Pregelatinized Starch 240.0 30.0 Sodium Starch glycolate 80.0 10.0 Calcium Carbonate 125.0 15.6 Magnesium Stearate Special 6.0 0.75 ______________________________________ *4- 4 4(hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 24 m.sup.2 /g.
TABLE 16 ______________________________________ Composition of 180 mg Tablets Amount Composition INGREDIENT mg/tablet % Weight ______________________________________ Piperidinoalkanol Compound* 180.0 30.0 Microcrystalline Cellulose 154 25.7 pregelatinzed starch 57.5 9.6 Lactose 154.0 25.7 Gelatin 21.2 3.5 Sodium Croscarmellose 28.8 4.8 Magnesium Stearate 4.5 0.75 ______________________________________ *4- 4 4(hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 24 m.sup.2 /g.
TABLE 17 ______________________________________ Composition of 60 mg Tablets Amount Composition INGREDIENT mg/tablet % Weight ______________________________________ Piperidinoalkanol Compound* 60.0 14.3 Microcrystalline Cellulose 141.0 33.7 Lactose 141.0 33.7 Pregelatinized Starch 40.0 9.6 Sodium Croscarmellose 20.0 4.8 Gelatin 14.7 3.5 Magnesium Stearate 2.1 0.5 ______________________________________ *4- 4 4(Hydroxydiphenylmethyl)-1-piperidinyl1-hydroxybutylα,dimethy benzeneacetic acid hydrochloride with a particle surface area of about 2-4 m.sup.2 /g.
TABLE 18 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 10.38 60 6.97 45 6.41 50 5.55 30 5.32 100 5.23 55 5.11 35 4.98 25 4.64 30 4.32 35 4.28 75 4.12 50 4.02 45 3.83 60 3.65 20 3.51 55 3.46 25 2.83 20 ______________________________________
TABLE 19 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 11.41 20 7.98 20 7.83 45 6.58 45 6.42 60 5.66 20 5.52 45 5.39 30 5.23 65 5.14 45 4.86 65 4.72 100 4.45 65 4.40 45 4.32 45 4.18 45 4.06 65 4.02 55 3.85 25 3.79 75 3.74 95 3.61 80 3.56 25 3.47 65 3.41 20 2.74 20 ______________________________________
TABLE 20 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 8.95 95 4.99 20 4.88 100 4.75 35 4.57 25 4.47 25 4.46 20 3.67 20 3.65 25 ______________________________________
TABLE 21 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 11.75 35 7.23 35 6.24 60 5.89 40 5.02 20 4.94 30 4.83 100 4.44 30 3.93 75 3.83 20 3.77 85 3.71 25 3.62 30 3.32 25 3.31 20 ______________________________________
TABLE 22 ______________________________________ D-Space, Angstroms Intensity, I/I.sub.O, % ______________________________________ 14.89 20 11.85 20 7.30 20 6.28 70 5.91 25 5.55 20 5.05 25 4.96 55 4.85 100 4.57 45 4.45 55 3.94 45 3.89 20 3.84 20 3.78 60 3.72 35 3.63 20 3.07 20 3.04 20 2.45 20 ______________________________________
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/948,005 US5932247A (en) | 1995-02-28 | 1997-10-09 | Pharmaceutical composition for piperidinoalkanol compounds |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39595295A | 1995-02-28 | 1995-02-28 | |
US55228795A | 1995-12-12 | 1995-12-12 | |
US08/742,166 US5738872A (en) | 1995-02-28 | 1996-11-01 | Pharmaceutical composition for piperidinoalkanol compounds |
US08/948,005 US5932247A (en) | 1995-02-28 | 1997-10-09 | Pharmaceutical composition for piperidinoalkanol compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/742,166 Division US5738872A (en) | 1995-02-28 | 1996-11-01 | Pharmaceutical composition for piperidinoalkanol compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US5932247A true US5932247A (en) | 1999-08-03 |
Family
ID=27015322
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/742,166 Expired - Lifetime US5738872A (en) | 1995-02-28 | 1996-11-01 | Pharmaceutical composition for piperidinoalkanol compounds |
US08/943,460 Expired - Lifetime US5855912A (en) | 1995-02-28 | 1997-10-03 | Pharmaceutical compositions for piperidinalkanol compounds |
US08/948,005 Expired - Lifetime US5932247A (en) | 1995-02-28 | 1997-10-09 | Pharmaceutical composition for piperidinoalkanol compounds |
US09/157,841 Expired - Lifetime US6113942A (en) | 1995-02-28 | 1998-09-21 | Pharmaceutical composition for piperidinoalkanol compounds |
US09/845,966 Abandoned US20010022973A1 (en) | 1995-02-28 | 2001-04-30 | Pharmaceutical composition for piperidinoalkanol compounds |
US10/039,798 Abandoned US20020106405A1 (en) | 1995-02-28 | 2002-01-04 | Pharmaceutical composition for piperidinoalkanol compounds |
US10/347,953 Abandoned US20030203020A1 (en) | 1995-02-28 | 2003-01-21 | Pharmaceutical compositions for piperidinoalkanol compounds |
US11/740,655 Abandoned US20070249671A1 (en) | 1995-02-28 | 2007-04-26 | Pharmaceutical composition for piperidinoalkanol compounds |
US12/565,410 Expired - Fee Related US8129408B2 (en) | 1995-02-28 | 2009-09-23 | Pharmaceutical composition for piperidinoalkanol compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/742,166 Expired - Lifetime US5738872A (en) | 1995-02-28 | 1996-11-01 | Pharmaceutical composition for piperidinoalkanol compounds |
US08/943,460 Expired - Lifetime US5855912A (en) | 1995-02-28 | 1997-10-03 | Pharmaceutical compositions for piperidinalkanol compounds |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/157,841 Expired - Lifetime US6113942A (en) | 1995-02-28 | 1998-09-21 | Pharmaceutical composition for piperidinoalkanol compounds |
US09/845,966 Abandoned US20010022973A1 (en) | 1995-02-28 | 2001-04-30 | Pharmaceutical composition for piperidinoalkanol compounds |
US10/039,798 Abandoned US20020106405A1 (en) | 1995-02-28 | 2002-01-04 | Pharmaceutical composition for piperidinoalkanol compounds |
US10/347,953 Abandoned US20030203020A1 (en) | 1995-02-28 | 2003-01-21 | Pharmaceutical compositions for piperidinoalkanol compounds |
US11/740,655 Abandoned US20070249671A1 (en) | 1995-02-28 | 2007-04-26 | Pharmaceutical composition for piperidinoalkanol compounds |
US12/565,410 Expired - Fee Related US8129408B2 (en) | 1995-02-28 | 2009-09-23 | Pharmaceutical composition for piperidinoalkanol compounds |
Country Status (22)
Country | Link |
---|---|
US (9) | US5738872A (en) |
EP (1) | EP0812195B1 (en) |
JP (3) | JP4105762B2 (en) |
KR (1) | KR100405116B1 (en) |
CN (1) | CN1090935C (en) |
AR (1) | AR003929A1 (en) |
AT (1) | ATE226819T1 (en) |
AU (1) | AU701042B2 (en) |
CA (1) | CA2213700C (en) |
CL (1) | CL2004000317A1 (en) |
DE (1) | DE69624559T2 (en) |
DK (1) | DK0812195T3 (en) |
ES (1) | ES2181868T3 (en) |
FI (1) | FI973518A0 (en) |
HU (1) | HUP9802086A3 (en) |
IL (1) | IL117237A (en) |
MX (1) | MX9706449A (en) |
NO (2) | NO325760B1 (en) |
NZ (1) | NZ302926A (en) |
PT (1) | PT812195E (en) |
TW (1) | TW460284B (en) |
WO (1) | WO1996026726A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177608A1 (en) * | 2001-04-09 | 2002-11-28 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US20020193603A1 (en) * | 1994-05-18 | 2002-12-19 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US6613906B1 (en) | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
US20040044038A1 (en) * | 2002-06-10 | 2004-03-04 | Barnaba Krochmal | Polymorphic form XVI of fexofenadine hydrochloride |
US20040167168A1 (en) * | 2001-04-09 | 2004-08-26 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
US20050090528A1 (en) * | 1994-05-18 | 2005-04-28 | Aventis Pharmaceticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20050256163A1 (en) * | 2004-04-26 | 2005-11-17 | Ilan Kor | Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
US20090012301A1 (en) * | 2004-09-28 | 2009-01-08 | Teva Pharmaceuticals Usa, Inc. | Fexofenadine crystal form and processes for its preparation thereof |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
US20100021547A1 (en) * | 1995-02-28 | 2010-01-28 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US11013730B1 (en) | 2014-09-12 | 2021-05-25 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091183B1 (en) * | 1996-12-03 | 2006-08-15 | Boston Medical Center Corporation | Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP) |
PT998272E (en) * | 1997-08-26 | 2003-09-30 | Aventis Pharma Inc | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALCANOL DECONGESTIONANT |
US6129932A (en) * | 1997-09-05 | 2000-10-10 | Merck & Co., Inc. | Compositions for inhibiting platelet aggregation |
US5914128A (en) * | 1997-12-22 | 1999-06-22 | Schering Corporation | Orally administrable solid dosage form |
US5916594A (en) * | 1997-12-22 | 1999-06-29 | Schering Corporation | Process of making solid ribavirin dosage forms |
DK0991415T3 (en) * | 1997-12-22 | 2003-06-16 | Schering Corp | Solid oral dosage forms for ribavirin and their method of preparation |
ES2193007T3 (en) * | 2000-02-17 | 2004-11-01 | Teva Pharmaceutical Industries Ltd. | STABLE PHARMACEUTICAL FORMULATION THAT INCLUDES MODIFICATION II OF TORSEMIDE. |
US8155096B1 (en) | 2000-12-01 | 2012-04-10 | Ipr Licensing Inc. | Antenna control system and method |
US20030022921A1 (en) * | 2001-02-21 | 2003-01-30 | Minutza Leibovici | Stable pharmaceutical formulation comprising torsemide modification II |
US6569454B2 (en) * | 2001-02-27 | 2003-05-27 | Minh Van Nguyen | Simple tablet compression using gelatin |
PT1414453E (en) * | 2001-07-31 | 2008-05-29 | Texcontor Ets | Fexofenadine hydrochloride polymorph |
US6723348B2 (en) * | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
PE20030762A1 (en) | 2001-12-18 | 2003-09-05 | Schering Corp | HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS |
GB0201508D0 (en) * | 2002-01-23 | 2002-03-13 | Novartis Ag | Organic compounds |
AU2003243191B2 (en) * | 2002-05-02 | 2007-09-20 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
AU2003208918A1 (en) * | 2003-01-03 | 2004-08-10 | Minh Nguyen | Simple tablet compression using gelatin |
US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
US20050220877A1 (en) * | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
PT1729735E (en) * | 2004-11-10 | 2007-08-06 | Teva Pharma | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
US8367105B2 (en) | 2004-11-10 | 2013-02-05 | Teva Pharmaceutical Industries, Ltd. | Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby |
PT1884242E (en) | 2005-05-26 | 2013-05-21 | Dainippon Sumitomo Pharma Co | Pharmaceutical composition comprising lurasidone |
KR100735904B1 (en) | 2005-08-02 | 2007-07-04 | 주식회사 드림파마 | Tablet composition containing extract of natural herbal plants and its manufacturing process |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
WO2007052310A2 (en) * | 2005-11-03 | 2007-05-10 | Morepen Laboratories Limited | Polymorphs of fexofenadine hydrochloride and process for their preparation |
ES2553805T3 (en) * | 2006-04-05 | 2015-12-11 | Opko Health, Inc. | Pharmaceutical formulations comprising salts of (5S, 8S) -8 - [{(1R) -1- (3,5-bis- (trifluoromethyl) phenyl] -ethoxy} -methyl] -8-phenyl-1,7-diazaspiro [4.5] decan-2-one and its medical use |
PE20081891A1 (en) | 2007-03-22 | 2008-12-27 | Opko Health Inc | TABLET FORMULATIONS CONTAINING SALTS OF 8 - [{1- (3,5-BIS- (TRIFLUOROMETIL) PHENYL) -ETOXY} -METIL] -8-PHENYL-1,7-DIAZA-SPIRO [4.5] DECAN-2- ONA AND TABLETS MADE FROM THESE |
US20100312338A1 (en) * | 2009-06-05 | 2010-12-09 | Entrigue Surgical, Inc. | Systems, devices and methods for providing therapy to an anatomical structure |
JP5860399B2 (en) | 2009-08-14 | 2016-02-16 | オプコ ヘルス, インコーポレイテッド | Intravenous formulation of neurokinin-1 antagonist |
FR2959130A1 (en) | 2010-04-21 | 2011-10-28 | Sanofi Aventis | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING ONE OR MORE ACTIVE INGREDIENTS AND COMPOSITIONS COMPRISING SAME |
FR2999937B1 (en) | 2012-12-21 | 2015-01-09 | Sanofi Sa | HIGH-FEXOFENADINE SOLID UNIT AND PROCESS FOR PREPARING THE SAME |
AR094761A1 (en) | 2013-02-14 | 2015-08-26 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES FEXOFENADINE AND PROCESS TO PREPARE THE SAME |
WO2015001478A1 (en) | 2013-07-01 | 2015-01-08 | Aventis Pharmaceuticals Inc. | Liquid pharmaceutical composition for oral administration comprising fexofenadine |
EP3002005A1 (en) * | 2014-09-30 | 2016-04-06 | Molkerei Meggle Wasserburg GmbH & Co. Kg | Direct compression excipient based on lactose, cellulose and starch |
KR101825041B1 (en) * | 2016-04-07 | 2018-02-02 | 주식회사 바이오솔루션 | Skin External composition for treating a wound comprising substance P |
Citations (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
FR2260348A2 (en) * | 1974-02-08 | 1975-09-05 | Richardson Merrell Inc | |
US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
US3979520A (en) * | 1973-09-26 | 1976-09-07 | Boehringer Mannheim G.M.B.H. | Preparation of rapidly resorbable glibenclamide |
US4060634A (en) * | 1973-09-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Rapidly resorbable glibenclamide |
US4196188A (en) * | 1976-11-30 | 1980-04-01 | Besins Jean Louis A | Orally administrable form of progesterone |
FR2453854A1 (en) * | 1979-04-10 | 1980-11-07 | Richardson Merrell Inc | NOVEL O- (4-DIPHENYLMETHYLPIPERIDINO) -1-PHENYLALCANOLS DERIVATIVES, ESPECIALLY USEFUL AS ANTIHISTAMINS, AND THEIR PREPARATION PROCESS |
US4254130A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4285958A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
EP0111114A2 (en) * | 1982-11-06 | 1984-06-20 | Telefonbau und Normalzeit GmbH | Circuit arrangement for a telephone exchange, expecially a private branch exchange with additional data communication |
EP0173293A2 (en) * | 1984-08-30 | 1986-03-05 | Merrell Dow Pharmaceuticals Inc. | Hot melt antihistamine formulations |
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
US4639458A (en) * | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
EP0310999A1 (en) * | 1987-10-07 | 1989-04-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
US4840799A (en) * | 1986-02-14 | 1989-06-20 | Lejus Medical Aktiebolag | Process for preparing rapidly disintegrating granulates |
EP0348683A1 (en) * | 1988-06-01 | 1990-01-03 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine |
US4916163A (en) * | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
US4963540A (en) * | 1986-04-16 | 1990-10-16 | Maxson Wayne S | Method for treatment of premenstrual syndrome |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
US5021242A (en) * | 1987-06-20 | 1991-06-04 | A. Nattermann & Cie Gmbh | Solid drug preparations containing micronized crystals of ebselen |
US5049568A (en) * | 1989-01-23 | 1991-09-17 | Merrell Dow Pharmaceuticals Inc. | Liquid pharmaceutical composition for piperidinoalkanol derivatives |
EP0468392A1 (en) * | 1990-07-27 | 1992-01-29 | Jagotec Ag | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
EP0396404B1 (en) * | 1989-05-03 | 1994-02-16 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
WO1994009761A1 (en) * | 1992-10-23 | 1994-05-11 | Schering Corporation | Stable extended release oral dosage composition |
US5375693A (en) * | 1992-08-03 | 1994-12-27 | Sepracor, Inc. | Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine |
WO1995001781A1 (en) * | 1993-07-09 | 1995-01-19 | Apr Applied Pharma Research Sa | Multilayered controlled-release oral solid pharmaceutical forms |
EP0636364A1 (en) * | 1993-07-27 | 1995-02-01 | McNEIL-PPC, INC. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5429825A (en) * | 1992-06-26 | 1995-07-04 | Mcneil-Ppc, Inc. | Rotomelt granulation |
US5472704A (en) * | 1991-05-30 | 1995-12-05 | Recordati S.A., Chemical And Pharmaceutical Company | Pharmaceutical controlled-release composition with bioadhesive properties |
US5487901A (en) * | 1993-05-31 | 1996-01-30 | Ekita Investments N.V. | Process for preparing pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4493528A (en) * | 1980-04-11 | 1985-01-15 | Board Of Trustees Of The Leland Stanford Junior University | Fiber optic directional coupler |
GB8613811D0 (en) * | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
SE8603812D0 (en) * | 1986-09-12 | 1986-09-12 | Draco Ab | ADMINISTRATION OF LIPOSOMES TO MAMMALS |
CN1053570C (en) * | 1987-10-07 | 2000-06-21 | 默尔多药物公司 | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
SE8804173A0 (en) * | 1988-11-18 | 1990-05-19 | Lim Johan Ab | insect traps |
US5376386A (en) * | 1990-01-24 | 1994-12-27 | British Technology Group Limited | Aerosol carriers |
SE9101090D0 (en) * | 1991-04-11 | 1991-04-11 | Astra Ab | PROCESS FOR CONDITIONING OF WATER-SOLUBLE SUBSTANCES |
US5516803A (en) * | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
CA2125666C (en) * | 1991-12-12 | 2002-07-16 | Rachel Ann Akehurst | Medicaments |
US5301664A (en) * | 1992-03-06 | 1994-04-12 | Sievers Robert E | Methods and apparatus for drug delivery using supercritical solutions |
AU671822B2 (en) | 1992-04-10 | 1996-09-12 | Aventisub Ii Inc. | 4-diphenylmethyl piperidine derivatives and process for their preparation |
JPH07506828A (en) | 1992-05-11 | 1995-07-27 | メレルダウファーマス−ティカルズ インコーポレイテッド | Use of terfenazine derivatives as antihistamines in patients with liver damage |
US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
SE9203743D0 (en) * | 1992-12-11 | 1992-12-11 | Astra Ab | EFFICIENT USE |
PT1026147E (en) * | 1993-06-24 | 2004-04-30 | Albany Molecular Res Inc | UTERIC COMPOUNDS AS INTERMEDIARIES IN THE PRODUCTION OF PIPERIDINE DERIVATIVES |
CA2128821A1 (en) * | 1993-07-27 | 1995-01-28 | Dilip J. Gole | Freeze-dried pharmaceutical dosage form and process for separation thereof |
WO1995010278A1 (en) * | 1993-10-15 | 1995-04-20 | Hoechst Marion Roussel, Inc. | Treatment of allergic disorders with terfenadine carboxylate |
US5451409A (en) * | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
MX9605613A (en) | 1994-05-18 | 1998-05-31 | Hoechst Marion Roussel Inc | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof. |
US20030045722A1 (en) | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
EP0812195B1 (en) * | 1995-02-28 | 2002-10-30 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
US5574045A (en) * | 1995-06-06 | 1996-11-12 | Hoechst Marion Roussel, Inc. | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form |
DE19720312A1 (en) * | 1997-05-15 | 1998-11-19 | Hoechst Ag | Preparation with increased in vivo tolerance |
ID24463A (en) * | 1997-08-14 | 2000-07-20 | Hoechst Marion Roussel Inc | METHOD OF IMPROVING THE AVAILABILITY OF PHYSOFENADIN AND ITS DECLARATION |
US6451815B1 (en) | 1997-08-14 | 2002-09-17 | Aventis Pharmaceuticals Inc. | Method of enhancing bioavailability of fexofenadine and its derivatives |
PT998272E (en) | 1997-08-26 | 2003-09-30 | Aventis Pharma Inc | PHARMACEUTICAL COMPOSITION FOR COMBINATION OF PIPERIDINOALCANOL DECONGESTIONANT |
-
1996
- 1996-01-26 EP EP96905292A patent/EP0812195B1/en not_active Revoked
- 1996-01-26 DK DK96905292T patent/DK0812195T3/en active
- 1996-01-26 WO PCT/US1996/001253 patent/WO1996026726A1/en active IP Right Grant
- 1996-01-26 ES ES96905292T patent/ES2181868T3/en not_active Expired - Lifetime
- 1996-01-26 PT PT96905292T patent/PT812195E/en unknown
- 1996-01-26 DE DE69624559T patent/DE69624559T2/en not_active Revoked
- 1996-01-26 HU HU9802086A patent/HUP9802086A3/en unknown
- 1996-01-26 NZ NZ302926A patent/NZ302926A/en not_active IP Right Cessation
- 1996-01-26 AT AT96905292T patent/ATE226819T1/en not_active IP Right Cessation
- 1996-01-26 MX MX9706449A patent/MX9706449A/en unknown
- 1996-01-26 KR KR1019970705981A patent/KR100405116B1/en not_active IP Right Cessation
- 1996-01-26 AU AU49098/96A patent/AU701042B2/en not_active Expired
- 1996-01-26 CN CN96192200A patent/CN1090935C/en not_active Expired - Lifetime
- 1996-01-26 JP JP52625796A patent/JP4105762B2/en not_active Expired - Lifetime
- 1996-01-26 CA CA002213700A patent/CA2213700C/en not_active Expired - Lifetime
- 1996-02-23 TW TW085102075A patent/TW460284B/en not_active IP Right Cessation
- 1996-02-23 IL IL11723796A patent/IL117237A/en not_active IP Right Cessation
- 1996-02-27 AR ARP960101530A patent/AR003929A1/en not_active Application Discontinuation
- 1996-11-01 US US08/742,166 patent/US5738872A/en not_active Expired - Lifetime
-
1997
- 1997-08-27 NO NO19973938A patent/NO325760B1/en not_active IP Right Cessation
- 1997-08-27 FI FI973518A patent/FI973518A0/en not_active Application Discontinuation
- 1997-10-03 US US08/943,460 patent/US5855912A/en not_active Expired - Lifetime
- 1997-10-09 US US08/948,005 patent/US5932247A/en not_active Expired - Lifetime
-
1998
- 1998-09-21 US US09/157,841 patent/US6113942A/en not_active Expired - Lifetime
-
2001
- 2001-04-30 US US09/845,966 patent/US20010022973A1/en not_active Abandoned
-
2002
- 2002-01-04 US US10/039,798 patent/US20020106405A1/en not_active Abandoned
-
2003
- 2003-01-21 US US10/347,953 patent/US20030203020A1/en not_active Abandoned
-
2004
- 2004-02-20 CL CL200400317A patent/CL2004000317A1/en unknown
- 2004-06-09 JP JP2004170680A patent/JP4177787B2/en not_active Expired - Lifetime
-
2006
- 2006-11-23 NO NO20065390A patent/NO20065390L/en not_active Application Discontinuation
-
2007
- 2007-04-26 US US11/740,655 patent/US20070249671A1/en not_active Abandoned
-
2008
- 2008-06-11 JP JP2008152525A patent/JP2008266347A/en active Pending
-
2009
- 2009-09-23 US US12/565,410 patent/US8129408B2/en not_active Expired - Fee Related
Patent Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3806526A (en) * | 1972-01-28 | 1974-04-23 | Richardson Merrell Inc | 1-aroylalkyl-4-diphenylmethyl piperidines |
US3878217A (en) * | 1972-01-28 | 1975-04-15 | Richardson Merrell Inc | Alpha-aryl-4-substituted piperidinoalkanol derivatives |
US3979520A (en) * | 1973-09-26 | 1976-09-07 | Boehringer Mannheim G.M.B.H. | Preparation of rapidly resorbable glibenclamide |
US4060634A (en) * | 1973-09-26 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Rapidly resorbable glibenclamide |
US3966949A (en) * | 1973-10-12 | 1976-06-29 | Richardson-Merrell Inc. | Pharmaceutical compositions and preparing same |
FR2260348A2 (en) * | 1974-02-08 | 1975-09-05 | Richardson Merrell Inc | |
US4196188A (en) * | 1976-11-30 | 1980-04-01 | Besins Jean Louis A | Orally administrable form of progesterone |
US4285958A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof |
US4254130A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4254129A (en) * | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
FR2453854A1 (en) * | 1979-04-10 | 1980-11-07 | Richardson Merrell Inc | NOVEL O- (4-DIPHENYLMETHYLPIPERIDINO) -1-PHENYLALCANOLS DERIVATIVES, ESPECIALLY USEFUL AS ANTIHISTAMINS, AND THEIR PREPARATION PROCESS |
US4285957A (en) * | 1979-04-10 | 1981-08-25 | Richardson-Merrell Inc. | 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof |
EP0111114A2 (en) * | 1982-11-06 | 1984-06-20 | Telefonbau und Normalzeit GmbH | Circuit arrangement for a telephone exchange, expecially a private branch exchange with additional data communication |
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
EP0173293A2 (en) * | 1984-08-30 | 1986-03-05 | Merrell Dow Pharmaceuticals Inc. | Hot melt antihistamine formulations |
US4639458A (en) * | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
US4916163A (en) * | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
US4840799A (en) * | 1986-02-14 | 1989-06-20 | Lejus Medical Aktiebolag | Process for preparing rapidly disintegrating granulates |
US4963540A (en) * | 1986-04-16 | 1990-10-16 | Maxson Wayne S | Method for treatment of premenstrual syndrome |
US5021242A (en) * | 1987-06-20 | 1991-06-04 | A. Nattermann & Cie Gmbh | Solid drug preparations containing micronized crystals of ebselen |
US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
EP0310999A1 (en) * | 1987-10-07 | 1989-04-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
US4999226A (en) * | 1988-06-01 | 1991-03-12 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination |
EP0348683A1 (en) * | 1988-06-01 | 1990-01-03 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine |
US5049568A (en) * | 1989-01-23 | 1991-09-17 | Merrell Dow Pharmaceuticals Inc. | Liquid pharmaceutical composition for piperidinoalkanol derivatives |
EP0396404B1 (en) * | 1989-05-03 | 1994-02-16 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
US5476654A (en) * | 1990-07-27 | 1995-12-19 | Jagotec Ag | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained |
EP0468392A1 (en) * | 1990-07-27 | 1992-01-29 | Jagotec Ag | Process for preparing pharmaceutical compositions having an increased active substance dissolution rate, and the compositions obtained |
US5271944A (en) * | 1991-04-05 | 1993-12-21 | Biofor, Ltd. | Pharmacologically enhanced formulations |
US5472704A (en) * | 1991-05-30 | 1995-12-05 | Recordati S.A., Chemical And Pharmaceutical Company | Pharmaceutical controlled-release composition with bioadhesive properties |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5429825A (en) * | 1992-06-26 | 1995-07-04 | Mcneil-Ppc, Inc. | Rotomelt granulation |
EP0582380B1 (en) * | 1992-06-26 | 1996-09-04 | McNEIL-PPC, INC. | Dry granulation using a fluidized bed |
US5375693A (en) * | 1992-08-03 | 1994-12-27 | Sepracor, Inc. | Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine |
WO1994009761A1 (en) * | 1992-10-23 | 1994-05-11 | Schering Corporation | Stable extended release oral dosage composition |
US5487901A (en) * | 1993-05-31 | 1996-01-30 | Ekita Investments N.V. | Process for preparing pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times |
WO1995001781A1 (en) * | 1993-07-09 | 1995-01-19 | Apr Applied Pharma Research Sa | Multilayered controlled-release oral solid pharmaceutical forms |
EP0636364A1 (en) * | 1993-07-27 | 1995-02-01 | McNEIL-PPC, INC. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
US5587172A (en) * | 1993-09-10 | 1996-12-24 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
Non-Patent Citations (2)
Title |
---|
Comprehensive Medicinal Chemistry, vol. 5, Biopharmaceutics, pp. 563 566 (1990). * |
Comprehensive Medicinal Chemistry, vol. 5, Biopharmaceutics, pp. 563-566 (1990). |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662835B2 (en) | 1994-05-18 | 2010-02-16 | Aventis Holdings, Inc. | Methods of treating allergic reactions using an anhydrous form of antihistaminic piperidine derivatives |
US20050090528A1 (en) * | 1994-05-18 | 2005-04-28 | Aventis Pharmaceticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20020193601A1 (en) * | 1994-05-18 | 2002-12-19 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20030045721A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US7135571B2 (en) | 1994-05-18 | 2006-11-14 | Aventis Pharmaceuticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20040014976A1 (en) * | 1994-05-18 | 2004-01-22 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20070021461A1 (en) * | 1994-05-18 | 2007-01-25 | Aventis Pharmaceuticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US7138524B2 (en) | 1994-05-18 | 2006-11-21 | Aventis Pharmaceuticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US7666881B2 (en) | 1994-05-18 | 2010-02-23 | Aventis Holdings, Inc. | Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives |
US20070021462A1 (en) * | 1994-05-18 | 2007-01-25 | Aventis Pharmaceuticals, Inc. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US20020193603A1 (en) * | 1994-05-18 | 2002-12-19 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
US8129408B2 (en) | 1995-02-28 | 2012-03-06 | Aventisub Ii Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
US20100021547A1 (en) * | 1995-02-28 | 2010-01-28 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol compounds |
US6613906B1 (en) | 2000-06-06 | 2003-09-02 | Geneva Pharmaceuticals, Inc. | Crystal modification |
US20090149497A1 (en) * | 2001-04-09 | 2009-06-11 | Teva Pharmaceuticals Usa, Inc. | Polymorphs of fexofenadine hydrochloride |
US20020177608A1 (en) * | 2001-04-09 | 2002-11-28 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
US20040058955A1 (en) * | 2001-04-09 | 2004-03-25 | Ben-Zon Dolitzky | Polymorphs of fexofenadine hydrochloride |
US20090012121A1 (en) * | 2001-04-09 | 2009-01-08 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine hydrochloride |
US20040167168A1 (en) * | 2001-04-09 | 2004-08-26 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
EP2266590A2 (en) | 2002-02-22 | 2010-12-29 | Shire LLC | Active agent delivery sytems and methods for protecting and administering active agents |
US20090054486A1 (en) * | 2002-06-10 | 2009-02-26 | Teva Pharmaceuticals Usa, Inc. | Polymorphic form xvi of fexofenadine hydrochloride |
US20060217557A1 (en) * | 2002-06-10 | 2006-09-28 | Barnaba Krochmal | Polymorphic form XVI of fexofenadine hydrochloride |
US7671071B2 (en) | 2002-06-10 | 2010-03-02 | Teva Pharmaceutical Industries Ltd. | Polymorphic Form XVI of fexofenadine hydrochloride |
US20040044038A1 (en) * | 2002-06-10 | 2004-03-04 | Barnaba Krochmal | Polymorphic form XVI of fexofenadine hydrochloride |
US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
US20050256163A1 (en) * | 2004-04-26 | 2005-11-17 | Ilan Kor | Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
US20090082398A1 (en) * | 2004-04-26 | 2009-03-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of fexofenadine hydrochloride and processes for their preparation |
US20090012301A1 (en) * | 2004-09-28 | 2009-01-08 | Teva Pharmaceuticals Usa, Inc. | Fexofenadine crystal form and processes for its preparation thereof |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
US11013730B1 (en) | 2014-09-12 | 2021-05-25 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5932247A (en) | Pharmaceutical composition for piperidinoalkanol compounds | |
US7666881B2 (en) | Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives | |
MX2007000911A (en) | Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol. | |
IL134772A (en) | Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form | |
US20240067644A1 (en) | Polymorphs of the hydrochloride salt of linaprazan glurate | |
GB2385268A (en) | Amlodipine free base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: AVENTIS PHARMACEUTICALS INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:HOECHST MARION ROUSSEL, INC.;REEL/FRAME:013986/0597 Effective date: 19991213 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment |
Year of fee payment: 7 |
|
AS | Assignment |
Owner name: HMR PHARMA INC., MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS PHARMACEUTICALS INC.;REEL/FRAME:020119/0606 Effective date: 20011228 |
|
AS | Assignment |
Owner name: AVENTIS HOLDINGS INC., DELAWARE Free format text: CHANGE OF NAME;ASSIGNOR:HMR PHARMA INC.;REEL/FRAME:020174/0006 Effective date: 20011228 |
|
AS | Assignment |
Owner name: AVENTISUB II INC.,DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS HOLDINGS INC.;REEL/FRAME:024006/0487 Effective date: 20081231 Owner name: AVENTISUB II INC., DELAWARE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVENTIS HOLDINGS INC.;REEL/FRAME:024006/0487 Effective date: 20081231 |
|
FPAY | Fee payment |
Year of fee payment: 12 |